dipyridamole has been researched along with Dementia Praecox in 5 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to examine the effects of dipyridamole monotherapy of 200 mg/day on positive and negative symptoms, with the goal of determining dosing for future adjunctive studies in schizophrenia." | 9.15 | Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling. ( Adami, H; Allen-Emerson, R; Gopinath, HV; Hong, LE; Liu, J; McMahon, RP; Thaker, GK; Wonodi, I, 2011) |
| "Dipyridamole may be of therapeutic benefit in treating schizophrenia in combination with neuroleptics." | 9.09 | Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. ( Akhondzadeh, S; Jamilian, H; Kamalipour, A; Shabestari, O; Shasavand, E, 2000) |
| "The aim of this study was to examine the effects of dipyridamole monotherapy of 200 mg/day on positive and negative symptoms, with the goal of determining dosing for future adjunctive studies in schizophrenia." | 5.15 | Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling. ( Adami, H; Allen-Emerson, R; Gopinath, HV; Hong, LE; Liu, J; McMahon, RP; Thaker, GK; Wonodi, I, 2011) |
| "Dipyridamole may be of therapeutic benefit in treating schizophrenia in combination with neuroleptics." | 5.09 | Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. ( Akhondzadeh, S; Jamilian, H; Kamalipour, A; Shabestari, O; Shasavand, E, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wonodi, I | 1 |
| Gopinath, HV | 1 |
| Liu, J | 1 |
| Adami, H | 1 |
| Hong, LE | 1 |
| Allen-Emerson, R | 1 |
| McMahon, RP | 1 |
| Thaker, GK | 1 |
| DELLAPORTA, P | 1 |
| MAIOLO, AT | 1 |
| ROSSELLA, E | 1 |
| Akhondzadeh, S | 1 |
| Shasavand, E | 1 |
| Jamilian, H | 1 |
| Shabestari, O | 1 |
| Kamalipour, A | 1 |
| Nako, Y | 1 |
| Tachibana, A | 1 |
| Fujiu, T | 1 |
| Tomomasa, T | 1 |
| Morikawa, A | 1 |
| Brunstein, MG | 1 |
| Belmonte-de-Abreu, P | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial of Dipyridamole in Schizophrenia[NCT00349973] | 29 participants (Actual) | Interventional | 2001-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Scale for the Assessment of Negative Symptoms (SANS) total score, minus the global items, inappropriate affect, poverty of content of speech, and attention items, used to measure negative symptoms. Mean SANS total score by treatment and week. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms. (NCT00349973)
Timeframe: Baseline and Follow-Up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (Phase 1/Week 1) | Follow-Up (Phase 4/Week 1) | |
| Dipyridamole | 23.3 | 25.8 |
| Olanzapine | 25.6 | 27.0 |
"The Brief Psychiatric Rating Scale (BPRS) consists of 20 items, with 6 of these items used to assess positive symptom change. The BPRS positive symptom items are: somatic concern, conceptual disorganization, hostility, suspiciousness, hallucinatory behavior, and unusual thought content. Each scale ranges from 1=Not Present to 7=Very Severe. A higher score indicates a more severe positive symptom rating." (NCT00349973)
Timeframe: Baseline and follow-up
| Intervention | units on a scale (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline - Somatic Concern | Follow-Up - Somatic Concern | Baseline - Conceptual Disorganization | Follow-Up - Conceptual Disorganization | Baseline - Hostility | Follow-Up - Hostility | Baseline - Suspiciousness | Follow-Up - Suspiciousness | Baseline - Hallucination | Follow-Up - Hallucination | Baseline - Unusual Thought Content | Follow-Up - Unusual Thought Content | |
| Dipyridamole | 2.222 | 1.60 | 2.667 | 2.00 | 1.222 | 1.00 | 4.11 | 3.000 | 2.67 | 2.600 | 3.111 | 2.800 |
| Olanzapine | 1.400 | 1.00 | 2.600 | 2.00 | 1.200 | 2.00 | 3.40 | 1.500 | 3.80 | 2.500 | 3.400 | 1.500 |
The RBANS is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory. The raw scores from the subtests are scaled together to create index scores, and these are summed for conversion to a total scale score. Higher score equals a better outcome. The total index score range for the RBANS is 40-160. (NCT00349973)
Timeframe: Baseline and Follow-Up
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (Phase 1/Week 1) | Follow-Up (Phase 3/Week 6) | |
| Dipyridamole | 73.00 | 77.40 |
| Olanzapine | 59.00 | 65.00 |
2 trials available for dipyridamole and Dementia Praecox
| Article | Year |
|---|---|
Dipyridamole monotherapy in schizophrenia: pilot of a novel treatment approach by modulation of purinergic signaling.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Dipyridamo | 2011 |
Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions.
Topics: Adult; Antipsychotic Agents; Dipyridamole; Drug Therapy, Combination; Female; Haloperidol; Humans; M | 2000 |
3 other studies available for dipyridamole and Dementia Praecox
| Article | Year |
|---|---|
[BEHAVIOR OF CEREBRAL BLOOD FLOW AND METABOLISM AFTER ADMINISTRATION OF 2,6 BIS-(DIETHANOLAMINO)-4,8 DIPIPERIDINO-PYRIMIDO(5,4 D)-PYRIMIDINE].
Topics: Alcoholism; Blood Flow Velocity; Blood Gas Analysis; Brain; Carbohydrate Metabolism; Cerebrovascular | 1963 |
Neonatal thrombocytosis resulting from the maternal use of non-narcotic antischizophrenic drugs during pregnancy.
Topics: Dipyridamole; Female; Humans; Infant, Newborn; Interleukin-6; Male; Neonatal Abstinence Syndrome; Ph | 2001 |
Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine-glutamate interactions.
Topics: Adenosine; Dipyridamole; Glutamic Acid; Humans; Phosphodiesterase Inhibitors; Receptors, Dopamine D2 | 2001 |